vs
Side-by-side financial comparison of HALOZYME THERAPEUTICS, INC. (HALO) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $300.5M, roughly 1.5× Hilltop Holdings Inc.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs -31.3%, a 44.3% gap on every dollar of revenue. Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs 0.6%).
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
HALO vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $451.8M | $300.5M |
| Net Profit | $-141.6M | $39.0M |
| Gross Margin | 82.6% | — |
| Operating Margin | -20.6% | — |
| Net Margin | -31.3% | 13.0% |
| Revenue YoY | 51.6% | — |
| Net Profit YoY | -203.3% | -12.4% |
| EPS (diluted) | $-1.13 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $451.8M | $329.9M | ||
| Q3 25 | $354.3M | $330.2M | ||
| Q2 25 | $325.7M | $303.3M | ||
| Q1 25 | $264.9M | $318.5M | ||
| Q4 24 | $298.0M | $301.1M | ||
| Q3 24 | $290.1M | $305.5M | ||
| Q2 24 | $231.4M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $-141.6M | $41.6M | ||
| Q3 25 | $175.2M | $45.8M | ||
| Q2 25 | $165.2M | $36.1M | ||
| Q1 25 | $118.1M | $42.1M | ||
| Q4 24 | $137.0M | $35.5M | ||
| Q3 24 | $137.0M | $29.7M | ||
| Q2 24 | $93.2M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 82.6% | — | ||
| Q3 25 | 84.4% | — | ||
| Q2 25 | 85.8% | — | ||
| Q1 25 | 81.7% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 82.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -20.6% | 16.1% | ||
| Q3 25 | 61.5% | 18.4% | ||
| Q2 25 | 62.2% | 16.3% | ||
| Q1 25 | 53.4% | 18.1% | ||
| Q4 24 | 58.9% | 14.7% | ||
| Q3 24 | 56.3% | 13.9% | ||
| Q2 24 | 50.7% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | -31.3% | 12.6% | ||
| Q3 25 | 49.5% | 13.9% | ||
| Q2 25 | 50.7% | 11.9% | ||
| Q1 25 | 44.6% | 13.2% | ||
| Q4 24 | 46.0% | 11.8% | ||
| Q3 24 | 47.2% | 9.7% | ||
| Q2 24 | 40.3% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $-1.13 | $0.68 | ||
| Q3 25 | $1.43 | $0.74 | ||
| Q2 25 | $1.33 | $0.57 | ||
| Q1 25 | $0.93 | $0.65 | ||
| Q4 24 | $1.06 | $0.55 | ||
| Q3 24 | $1.05 | $0.46 | ||
| Q2 24 | $0.72 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.8M | — |
| Total DebtLower is stronger | $2.1B | $990.8M |
| Stockholders' EquityBook value | $48.8M | $2.2B |
| Total Assets | $2.5B | $15.7B |
| Debt / EquityLower = less leverage | 43.89× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $133.8M | — | ||
| Q3 25 | $419.7M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $176.3M | — | ||
| Q4 24 | $115.8M | — | ||
| Q3 24 | $154.3M | — | ||
| Q2 24 | $187.9M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $48.8M | $2.2B | ||
| Q3 25 | $503.9M | $2.2B | ||
| Q2 25 | $332.7M | $2.2B | ||
| Q1 25 | $482.3M | $2.2B | ||
| Q4 24 | $363.8M | $2.2B | ||
| Q3 24 | $452.7M | $2.2B | ||
| Q2 24 | $289.4M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $2.5B | $15.8B | ||
| Q3 25 | $2.2B | $15.6B | ||
| Q2 25 | $2.1B | $15.4B | ||
| Q1 25 | $2.2B | $15.8B | ||
| Q4 24 | $2.1B | $16.3B | ||
| Q3 24 | $2.1B | $15.9B | ||
| Q2 24 | $2.0B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $219.0M | — |
| Free Cash FlowOCF − Capex | $217.6M | — |
| FCF MarginFCF / Revenue | 48.2% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $644.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $219.0M | $-38.7M | ||
| Q3 25 | $178.6M | $273.0M | ||
| Q2 25 | $99.7M | $-234.6M | ||
| Q1 25 | $154.2M | $5.8M | ||
| Q4 24 | $178.5M | $273.9M | ||
| Q3 24 | $115.4M | $515.6M | ||
| Q2 24 | $55.8M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $217.6M | $-55.5M | ||
| Q3 25 | $175.6M | $271.0M | ||
| Q2 25 | $98.1M | $-234.6M | ||
| Q1 25 | $153.3M | $5.0M | ||
| Q4 24 | $175.4M | $266.8M | ||
| Q3 24 | $113.9M | $513.8M | ||
| Q2 24 | $53.2M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | 48.2% | -16.8% | ||
| Q3 25 | 49.6% | 82.1% | ||
| Q2 25 | 30.1% | -77.4% | ||
| Q1 25 | 57.9% | 1.6% | ||
| Q4 24 | 58.9% | 88.6% | ||
| Q3 24 | 39.3% | 168.2% | ||
| Q2 24 | 23.0% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 5.1% | ||
| Q3 25 | 0.9% | 0.6% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | 0.4% | 0.3% | ||
| Q4 24 | 1.0% | 2.4% | ||
| Q3 24 | 0.5% | 0.6% | ||
| Q2 24 | 1.1% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.93× | ||
| Q3 25 | 1.02× | 5.96× | ||
| Q2 25 | 0.60× | -6.50× | ||
| Q1 25 | 1.31× | 0.14× | ||
| Q4 24 | 1.30× | 7.71× | ||
| Q3 24 | 0.84× | 17.36× | ||
| Q2 24 | 0.60× | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
